Marketing firm, ramarketing, has recently undergone a significant rebranding effort to better align with the evolving needs of post-COVID pharmaceutical and biotech marketing. The move aims to demonstrate a commitment to closely aligning with client challenges and commercial needs. The rebrand signifies a shift away from traditional marketing and service delivery to becoming a true commercial growth partner. The agency’s objectives include utilizing data and AI to better serve clients globally and diversifying its commercial offering to attract forward-thinking, dynamic organizations seeking a partnership.
According to CEO Emma Banks, the rebrand reflects the impact of industry changes and the company’s dedication to meeting such changes head-on. The revitalization of the brand also signifies a culture and opportunity evolution for the agency’s growing 80-strong global team, offering growth and development opportunities and promoting collaboration and expertise-sharing.
Furthermore, the agency’s private equity investor, NorthEdge, views the rebrand as a testament to the agency’s potential to spearhead a new era of growth, build upon its commercial thinking, and innovative approach. In addition, the opening of a new Toronto office last year and three locations across Europe and North America present significant growth potential.
Overall, through this strategic rebrand, ramarketing has positioned itself to redefine what it means to be a commercial growth partner and provide innovative, data-driven solutions that better serve clients globally.
By Matthew Neville – Senior Correspondent, Bdaily
In need of promoting your product/service to SME businesses in your region? Check out how Bdaily can help →